BioPlus Acquisition in an amended S-1 filing lowered its propsoed deal size to 18 million units, down from the 22 million initially registered in July for the offering.
A unit now consists of one Class A ordinary share and one-half of a warrant; whole warrants exercisable at $11.50.
The new SPAC is targeting the life sciences sector.
BioPlus is led by Chairman Jonathan Rigby, who has more than 30 years of experience leading private and publicly traded biotechnology and pharmaceutical companies in the US, UK, and Israel. Rigby is currently president, Group CEO and director at Revolo Biotherapeutics.
Cantor is sole book-running manager of the offering. The underwriters have an over-allotment option to purchase up to an additional 2.7 million units.
The SPAC said it has applied for a listing on the Nasdaq under BIOS.U. Read more.
